TY - JOUR AU - Welch, S. AU - Sharland, M. AU - Lyall, E. G. AU - Tudor-Williams, G. AU - Niehues, T. AU - Wintergerst, U. PY - 2009 DA - 2009// TI - PENTA 2009 guidelines for the use of antiretroviral therapy in paediatric HIV-1 infection JO - HIV medicine VL - 10 UR - https://doi.org/10.1111/j.1468-1293.2009.00759.x DO - 10.1111/j.1468-1293.2009.00759.x ID - Welch2009 ER - TY - CHAP PY - 2009 DA - 2009// TI - Guidelines for the Use of Antiretroviral Agents in Pediatric BT - HIV Infection ID - ref2 ER - TY - JOUR AU - Violari, A. AU - Cotton, M. F. AU - Gibb, D. M. AU - Babiker, A. G. AU - Steyn, J. AU - Madhi, S. A. PY - 2008 DA - 2008// TI - Early antiretroviral therapy and mortality among HIV-infected infants JO - N Engl J Med VL - 359 UR - https://doi.org/10.1056/NEJMoa0800971 DO - 10.1056/NEJMoa0800971 ID - Violari2008 ER - TY - JOUR AU - Goetghebuer, T. AU - Haelterman, E. AU - Le Chenadec, J. AU - Dollfus, C. AU - Gibb, D. AU - Judd, A. PY - 2009 DA - 2009// TI - Effect of early antiretroviral therapy on the risk of AIDS/death in HIV-infected infants JO - AIDS (London, England) VL - 23 UR - https://doi.org/10.1097/QAD.0b013e328326ca37 DO - 10.1097/QAD.0b013e328326ca37 ID - Goetghebuer2009 ER - TY - STD TI - PENPACT-1 First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial. The Lancet infectious diseases. Jan 31 ID - ref5 ER - TY - JOUR AU - Aboulker, J. P. AU - Babiker, A. AU - Chaix, M. L. AU - Compagnucci, A. AU - Darbyshire, J. AU - Debre, M. PY - 2004 DA - 2004// TI - Highly active antiretroviral therapy started in infants under 3 months of age: 72-week follow-up for CD4 cell count, viral load and drug resistance outcome JO - AIDS (London, England) VL - 18 UR - https://doi.org/10.1097/00002030-200401230-00013 DO - 10.1097/00002030-200401230-00013 ID - Aboulker2004 ER - TY - JOUR AU - Shearer, W. T. AU - Quinn, T. C. AU - LaRussa, P. AU - Lew, J. F. AU - Mofenson, L. AU - Almy, S. PY - 1997 DA - 1997// TI - Viral load and disease progression in infants infected with human immunodeficiency virus type 1. Women and Infants Transmission Study Group JO - N Engl J Med VL - 336 UR - https://doi.org/10.1056/NEJM199705083361901 DO - 10.1056/NEJM199705083361901 ID - Shearer1997 ER - TY - JOUR AU - Gulick, R. M. AU - Ribaudo, H. J. AU - Shikuma, C. M. AU - Lalama, C. AU - Schackman, B. R. AU - Meyer, W. A. PY - 2006 DA - 2006// JO - Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial. Jama VL - 296 ID - Gulick2006 ER - TY - JOUR AU - Luzuriaga, K. AU - McManus, M. AU - Mofenson, L. AU - Britto, P. AU - Graham, B. AU - Sullivan, J. L. PY - 2004 DA - 2004// TI - A trial of three antiretroviral regimens in HIV-1-infected children JO - N Engl J Med VL - 350 UR - https://doi.org/10.1056/NEJMoa032706 DO - 10.1056/NEJMoa032706 ID - Luzuriaga2004 ER - TY - JOUR AU - Melvin, A. J. AU - Lewis, P. F. AU - Mohan, K. M. AU - Naugler, W. S. AU - Frenkel, L. M. PY - 2002 DA - 2002// TI - Efficacy and toxicity of antiretroviral therapy using 4 or more agents: application of a strategy for antiretroviral management in human immunodeficiency virus-infected children JO - Archives of pediatrics & adolescent medicine VL - 156 UR - https://doi.org/10.1001/archpedi.156.6.568 DO - 10.1001/archpedi.156.6.568 ID - Melvin2002 ER - TY - JOUR AU - Orkin, C. AU - Stebbing, J. AU - Nelson, M. AU - Bower, M. AU - Johnson, M. AU - Mandalia, S. PY - 2005 DA - 2005// TI - A randomized study comparing a three- and four-drug HAART regimen in first-line therapy (QUAD study) JO - J Antimicrob Chemother VL - 55 UR - https://doi.org/10.1093/jac/dkh515 DO - 10.1093/jac/dkh515 ID - Orkin2005 ER - TY - JOUR AU - Starr, S. E. AU - Fletcher, C. V. AU - Spector, S. A. AU - Yong, F. H. AU - Fenton, T. AU - Brundage, R. C. PY - 1999 DA - 1999// TI - Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. Pediatric AIDS Clinical Trials Group 382 Team JO - N Engl J Med VL - 341 UR - https://doi.org/10.1056/NEJM199912163412502 DO - 10.1056/NEJM199912163412502 ID - Starr1999 ER - TY - CHAP AU - Tudor-Williams, G. AU - Head, S. AU - Weigel, R. AU - Valerius, N. H. AU - Ridell, A. AU - Lyall, E. G. PY - 2002 DA - 2002// TI - Baby Cocktail! A protease-sparing 4 drug combination for symptomatic infants BT - International Conference on AIDS ID - Tudor-Williams2002 ER - TY - CHAP PY - 2004 DA - 2004// BT - National Institutes of Health, Division of AIDS Table for Grading the Severety of Adult and Pediatric Adverse Events, version 1.0 ID - ref14 ER - TY - JOUR AU - Shearer, W. T. AU - Rosenblatt, H. M. AU - Gelman, R. S. AU - Oyomopito, R. AU - Plaeger, S. AU - Stiehm, E. R. PY - 2003 DA - 2003// TI - Lymphocyte subsets in healthy children from birth through 18 years of age: the Pediatric AIDS Clinical Trials Group P1009 study JO - J Allergy Clinical Immunol VL - 112 UR - https://doi.org/10.1016/j.jaci.2003.07.003 DO - 10.1016/j.jaci.2003.07.003 ID - Shearer2003 ER - TY - STD TI - Neubert J, Laws HJ, Adams O, Munk C, Kramer M, Niehues T, et al.: HIV-1 seroreversion following antiretroviral therapy in an HIV-infected child initially presenting with acquired immunodeficiency syndrome.AIDS (London, England)24(2):327–8. ID - ref16 ER - TY - JOUR AU - Chiappini, E. AU - Galli, L. AU - Tovo, P. A. AU - Gabiano, C. AU - Gattinara, G. C. AU - Guarino, A. PY - 2006 DA - 2006// TI - Virologic, immunologic, and clinical benefits from early combined antiretroviral therapy in infants with perinatal HIV-1 infection JO - AIDS (London, England) VL - 20 UR - https://doi.org/10.1097/01.aids.0000200529.64113.3e DO - 10.1097/01.aids.0000200529.64113.3e ID - Chiappini2006 ER - TY - JOUR AU - Chiappini, E. AU - Galli, L. AU - Tovo, P. A. AU - Gabiano, C. AU - Lisi, C. AU - Bernardi, S. PY - 2009 DA - 2009// TI - Five-year follow-up of children with perinatal HIV-1 infection receiving early highly active antiretroviral therapy JO - BMC infectious diseases VL - 9 UR - https://doi.org/10.1186/1471-2334-9-140 DO - 10.1186/1471-2334-9-140 ID - Chiappini2009 ER -